3 New Strong Buy Ratings from Top-Rated Analysts: 10/21/2026
Here are 3 stocks that Wall Street’s best minds are watching right now:
- Generac Holdings (GNRC): Amazon deal and data center sales drive big upside targets
- Amneal Pharmaceuticals (AMRX): FDA approval strengthens specialty portfolio, zero Hold ratings
- Kronos Worldwide (KRO): A global shortage lifts prices
P.S. Get more alerts like this daily … Try WallStreetZen Premium.
A note from our sponsors...
This Tiny Sub–$1 Gold-Silver Royalty Stock Is Ready to Run
Record revenue. Producing gold and silver assets. The biggest transaction in company history. And shares still largely undiscovered below $1. This tiny royalty firm puts its capital to work in carefully selected mining projects in exchange for a share of the gold and silver produced. Now that compounding machine is shifting into a much higher gear – backed by a powerful deal-flow advantage and some of the smartest money in the sector.
The window to get in early may be closing fast.
1. Kronos Worldwide (NYSE: KRO)
This pigments and paint manufacturing company is benefiting from a global sulfur shortage that is driving TiO2 prices higher, creating a favorable pricing environment that has propelled shares over 70% higher year-to-date.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $7.32 — get current quote
Max 1-year forecast: $9.00
Why we're watching:
- KRO has limited, but overall bullish, coverage among the analysts we track, with 1 Strong Buy recommendation. See all recommendations here
- For example, Deutsche Bank researcher David Begleiter (a top 14% rated analyst) recently maintained his Strong Buy with a price target representing 21% upside potential from current levels.
- Industry ranking context: KRO is currently the #4 highest-rated stock in the Specialty Chemical industry, which has an Industry Rating of A.
- Zen Ratings highlights: KRO earns an overall A rating, equal to a Strong Buy recommendation. Stocks with this rating have historically beaten the S&P significantly, delivering strong annual returns to investors.
- Component Grades: KRO excels with an A for Growth, while also maintaining strong Bs for Momentum, Sentiment, and Safety, indicating the company combines improving fundamentals with solid structural positioning in a favorable commodity cycle. See all 7 Component Grades here
2. Amneal Pharmaceuticals (NASDAQ: AMRX)
Recent FDA approval and launch of Lanreotide Injection has strengthened the company's specialty portfolio, driving optimism around future growth potential.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $19.45 — get current quote
Max 1-year forecast: $27.00
Why we're watching:
- AMRX has solid, bullish coverage among the analysts we track, with 3 Strong Buy, 2 Buy, and 0 Hold recommendations. See all recommendations here
- For example, JP Morgan researcher Chris Schott (a top 10% rated analyst) recently reinstated his Strong Buy with a price target well above current levels.
- More impressively, UBS researcher Ashwani Verma (a top 12% rated analyst) maintained his Strong Buy with a price target roughly 30% upside potential from current levels.
- Industry ranking context: AMRX is currently the #5 highest-rated stock in the Pharmaceutical industry, which has an Industry Rating of B.
- Zen Ratings highlights: AMRX earns an overall A rating, which is equivalent to a Strong Buy recommendation. This designation reflects stocks that passed a rigorous 115-factor fundamental review and represent the elite top 5% of all companies tracked.
- Component Grades: AMRX stands out with an A for Sentiment, reflecting strong analyst confidence in the company's specialty pharma strategy, while also earning solid Bs for Growth and Momentum, a mix that suggests building a positive trajectory. See all 7 Component Grades here
3. Generac Holdings (NYSE: GNRC)
This generator company has entered a massive deal with Amazon and is capitalizing on accelerating data center sales, creating new revenue streams beyond its traditional residential backup power stronghold.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $194.49 — get current quote
Max 1-year forecast: $375.00
Why we're watching:
- GNRC has strong, bullish coverage among the analysts we track, with 12 Strong Buy, 1 Buy, and 3 Hold recommendations. See all recommendations here
- For example, Stifel Nicolaus researcher Stephen Gengaro (a top 5% rated analyst) recently maintained his Strong Buy recommendation with a price target over 50% above current levels.
- But the highest price target actually suggests the stock could see greater than 90% upside in the coming year. The analysts generally reflect confidence in the company's data center and commercial momentum.
- Industry ranking context: GNRC is currently the #3 highest-rated stock in the Specialty Industrial Machinery industry, which has an Industry Rating of C.
- Zen Ratings highlights: GNRC earns an overall A rating, which amounts to a Strong Buy recommendation. Stocks with this rating have historically delivered nearly 30% annual returns, soundly beating the S&P.
- Component Grades: GNRC demonstrates exceptional growth potential with an A for Growth, complemented by respectable Bs for Safety and Financials, indicating the company combines robust expansion prospects with solid operational fundamentals. See all 7 Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.